Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Oncolines®2024-11-19T13:47:41+01:00
Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib Oncolines®2024-11-19T13:22:41+01:00
Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Oncolines®2024-11-19T13:29:24+01:00
Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Oncolines®2024-11-19T13:34:48+01:00
Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Oncolines®2024-11-19T13:18:25+01:00